Search
Calanolide A
go.drugbank.com/drugs/DB04886InvestigationalBoth drugs are being developed by Sarawak Pharmaceuticals. A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalApproximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. … Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth.
Ribostamycin
go.drugbank.com/drugs/DB03615ApprovedWithdrawnRibostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Diazepinomicin
go.drugbank.com/drugs/DB12420InvestigationalDiscovered using Thallion’s DECIPHER technology, diazepinomicin has completed preclinical studies conducted by the National Cancer Institute and Thallion to establish safety and efficacy in animal and … It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C.
Trestolone
go.drugbank.com/drugs/DB05830InvestigationalTrestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods.
Dabocemagene autoficel
go.drugbank.com/drugs/DB17878InvestigationalIt comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. … Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797]
Synonyms: TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/POCCR5 mAb
go.drugbank.com/drugs/DB05906ExperimentalIt was generated by HGS using the Abgenix XenoMouse technology. … CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (
Pimicotinib
go.drugbank.com/drugs/DB18972InvestigationalIt was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]
Maxy-G34
go.drugbank.com/drugs/DB05718Investigationalwild type human G-CSF to avoid PEGylation of such sites. … This was accomplished by removing the three lysine residues at positions 16, 34 and 40, and replacing them with arginine, and substituting two new lysine residues at positions 105 and 159.
Delorazepam
go.drugbank.com/drugs/DB01511IllicitInvestigationalIt is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam. … In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy.